Zomedica Corp. (ZOMDF) stock
ZOMDFOTCPharmaceutical PreparationsFiscal year ends December 31
$0.08−0.00 (-0.55%)
Close on Oct 19, 2026Market cap $77.40MP/E –Yield –
Zomedica revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Zomedica's revenue for the twelve months ending Jun 30, 2026 was $36.88M, up 30.1% year over year. For fiscal 2025 it was $32.03M, up 17.4% from the year before. The highest annual figure on record is $32.03M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.03M | +17.4% |
| FY2024 | Dec 31, 2024 | $27.29M | +8.3% |
| FY2023 | Dec 31, 2023 | $25.19M | +33.0% |
| FY2022 | Dec 31, 2022 | $18.93M | +358.0% |
| FY2021 | Dec 31, 2021 | $4.13M | – |
| FY2020 | Dec 31, 2020 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $9.51M | +36.6% |
| Q1 FY2026 | Mar 31, 2026 | $8.80M | +35.4% |
| Q4 FY2025 | Dec 31, 2025 | $10.47M | +32.6% |
| Q3 FY2025 | Sep 30, 2025 | $8.10M | +15.7% |
| Q2 FY2025 | Jun 30, 2025 | $6.96M | +13.6% |
| Q1 FY2025 | Mar 31, 2025 | $6.50M | +3.8% |
| Q4 FY2024 | Dec 31, 2024 | $7.90M | +7.6% |
| Q3 FY2024 | Sep 30, 2024 | $7.00M | +10.2% |
| Q2 FY2024 | Jun 30, 2024 | $6.13M | +1.8% |
| Q1 FY2024 | Mar 31, 2024 | $6.26M | +14.2% |
| Q4 FY2023 | Dec 31, 2023 | $7.34M | +19.2% |
| Q3 FY2023 | Sep 30, 2023 | $6.35M | +32.9% |
| Q2 FY2023 | Jun 30, 2023 | $6.02M | +41.8% |
| Q1 FY2023 | Mar 31, 2023 | $5.48M | +46.1% |
| Q4 FY2022 | Dec 31, 2022 | $6.16M | +50.9% |
| Q3 FY2022 | Sep 30, 2022 | $4.78M | +20665.2% |
| Q2 FY2022 | Jun 30, 2022 | $4.25M | +26437.5% |
| Q1 FY2022 | Mar 31, 2022 | $3.75M | +26692.9% |
| Q4 FY2021 | Dec 31, 2021 | $4.08M | – |
| Q3 FY2021 | Sep 30, 2021 | $23.00K | – |
| Q2 FY2021 | Jun 30, 2021 | $16.00K | – |
| Q1 FY2021 | Mar 31, 2021 | $14.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $0 | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
See a number that looks wrong?